The Associated Press Sep 23, 2026, 9:00 AM Cellares and Seoul National University Hospital launch proof-of-concept for automated manufacturing of gene-modified HSPC therapy on the Cell Shuttle(R) platform. SOUTH SAN FRANCISCO, Calif.-(BUSINESS WIRE)-Sep 23, 2026- Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and Seoul National University Hospital (SNUH), a leading translational medical center in South Korea, today announced a partnership to evaluate automated manufacturing for a gene-modified hematopoietic stem and progenitor cell (HSPC) therapy targeting paroxysmal nocturnal hemoglobinuria (PNH) on Cellares' Cell Shuttle platform. The collaboration will evaluate the translation of SNUH's gene-modified HSPC manufacturing process to the Cell Shuttle, with a focus on supporting a two-step transfection workflow, through the use of Cellares fully integrated and single-use electroporation module. The partnership marks Cellares' second collaboration in Asia and expands the company's collaboration network in the Asia-Pacific region as it supports SNUH's program toward clinical development in the United States. SNUH is an elite translational medical center that collaborates with leading global institutions on gene-modified hematopoietic stem cell therapies. Through the partnership, Cellares will support preclinical development and IND-enabling manufacturing workflows for SNUH's PNH program, with the goal of establishing a scalable manufacturing strategy for future U.S. clinical development. "Advancing gene-modified HSPC therapies requires a manufacturing approach that can support both the complexity of the process and the rigor of clinical translation," said Professor Youngil Koh, Director of the SNUH GMP Facility. "By working with Cellares, we are evaluating how automation can strengthen manufacturing reliability and scalability as we advance this program toward clinical development." "Gene-modified HSPC therapies are a natural fit for the Cell Shuttle and an area where Cellares has established manufacturing expertise," said Fabian Gerlinghaus, Co-Founder and CEO of Cellares. "By automating complex workflows, including electroporation, we can deliver the scalability, reliability and manufacturing economics required to advance these therapies through clinical development. This partnership extends that capability to SNUH as it prepares its PNH program for future clinical development in the United States." Gene-modified HSC manufacturing remains labor-intensive, variable and difficult to scale, limiting clinical development, increasing manufacturing costs and constraining patient access. The Cell Shuttle is an end-to-end automated cell therapy manufacturing platform designed to improve the scalability and reliability of autologous cell therapy manufacturing. The proof-of-concept will assess the potential to automate SNUH's manufacturing process on the Cell Shuttle, with the goal of improving reliability, driving down manufacturing costs and supporting broader patient access as the program advances. About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO), providing global cell therapy development and manufacturing services through an Industry 4.0 approach to the mass manufacture of the living drugs of the 21st century. The company enables drug sponsors to develop, scale, and commercialize cell therapies with the capacity, reliability, and economics required to meet total patient demand. Cellares' fully automated platforms - Cell Shuttle(R) for end-to-end cell therapy manufacturing and Cell Q(TM) for automated in-process and release quality control - are deployed across its network of IDMO Smart Factories worldwide. These technologies deliver industry-leading manufacturing economics, higher process success rates, and the ability to produce up to 10x more cell therapy batches than conventional CDMOs with comparable footprint and headcount, resulting in the lowest cost of manufacturing in the industry. The Cell Shuttle is the first cell therapy manufacturing platform to receive the FDA's Advanced Manufacturing Technology (AMT) designation, and has demonstrated a 100% automation success rate across more than a dozen automated processes. Cellares was also accepted into the FDA's inaugural Manufacturing PreCheck cohort, the only cell therapy platform among seven companies nationwide, giving Cellares early and ongoing engagement with the FDA during facility development and application submission periods, compressing regulatory timelines and de-risking the path to commercial-scale production for the drug sponsors building on Cellares' platform. Cellares has achieved key clinical validation milestones, including a successful IND Amendment enabling active clinical manufacturing on the Cell Shuttle platform, and the successful dosing of first patients in a partner clinical trial - marking the platform's transition from development-stage technology to clinically validated manufacturing infrastructure. These milestones span multiple therapeutic areas and cell therapy modalities, including both oncology and autoimmune indications. Headquartered in South San Francisco, California, Cellares operates its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey, with additional facilities under construction in Europe and Japan. Through its global manufacturing network, Cellares is purpose-built to support both clinical and commercial programs and to expand access to life-saving cell therapies worldwide. For more information, visit www.cellares.com and follow Cellares on LinkedIn. About Seoul National University Hospital Seoul National University Hospital (SNUH) is a medical center in South Korea dedicated to advancing patient care through the integration of education, research and clinical practice. SNUH works to advance state-of-the-art medical care and expand knowledge through medical research, while fostering the next generation of global healthcare leaders. As a translational medical center, SNUH also collaborates with leading institutions worldwide on the development of innovative therapies, including gene-modified hematopoietic stem cell-based treatments. Its institutional mission emphasizes excellence across medical care, research and education. Business Development:[email protected] Investors:[email protected] Media:[email protected] National University Hospital Contacts PR Contact:[email protected] KEYWORD: SOUTH KOREA UNITED STATES NORTH AMERICA ASIA PACIFIC CALIFORNIA INDUSTRY KEYWORD: RESEARCH GENERAL HEALTH PHARMACEUTICAL HOSPITALS GENETICS CLINICAL TRIALS SCIENCE BIOTECHNOLOGY STEM CELLS FDA OTHER SCIENCE HEALTH PUB: 09/23/2026 08:00 AM/DISC: 09/23/2026 08:00 AM

Cellares links with GenomeFrontier to test automation approach for virus-free CAR-Ts. Automated manufacturing specialist Cellares is teaming up with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the IDMO's Cell Shuttle platform for production of virus-free CAR-T therapies. The partnership will focus on the compatibility of GenomeFrontier's virus-free manufacturing process with Cellares' Cell Shuttle platform, with the goal of producing the Taiwanese biotech's investigational cell therapy GF-CART01. The CAR-T asset, at phase 1 in its most advanced program, is being developed to treat B-cell malignancies that include diffuse large B-cell lymphoma, follicular lymphoma, primary mediastinal large B-cell lymphoma and high-grade B-cell lymphoma, according to a Sept. 16 release. Unlike today's crop of commercially approved CAR-T therapies that rely on viral vectors, GenomeFrontier is pursuing a virus-free manufacturing approach that research suggests could eliminate manufacturing costs and complexities in the production process, among other potential benefits. Financial details of the collaboration weren't disclosed. The deal, which is Cellares' first development collaboration in Asia, will concentrate on supporting transfection unit operations by leveraging the contract manufacturers' integrated electroporator, which uses electrical pulses to create a physical opening in a cell's membrane. Transfection, meanwhile, refers to the process of introducing other material into those cells. "GenomeFrontier's virus-free approach reflects the increasing complexity of next-generation cell therapy manufacturing," Fabian Gerlinghaus, Cellares' co-founder and chief executive, said in a statement. "The Cell Shuttle is built to automate complex processes, including electroporation-based workflows, with the scalability and reliability needed as therapies advance through clinical development." Cellares touts its Cell Shuttle, roughly the size of a conference room, as a true end-to-end automated manufacturing platform for cell therapies. The technology, which Cellares argues can improve batch yield and success rates while lowering production costs, is paired with the company's companion platform Cell Q for automated in-process and release quality control. News of the partnership comes fast on the heels of Cellares' announced plans to reduce its workforce in California and New Jersey to the tune of about 168 jobs following the loss of a "large pharmaceutical customer." The development was first announced on LinkedIn by Gerlinghaus in August. Multiple sources have since reported the customer was Bristol Myers Squibb, which first linked up with Cellares in 2024 as part of a deal then potentially worth $380 million.